Adult T-cell leukaemia/lymphoma (ATLL) is a highly aggressive haematological malignancy. More than 40 cases of ATLL treated by allogeneic bone marrow transplantation (BMT) from sibling donors have been reported, while there have been only a few cases of unrelated BMT for treatment of this disease. We began performing allogeneic BMT from unrelated donors in 1999 to improve the outcome of ATLL patients with no suitable sibling donors. Eight ATLL patients underwent unrelated BMT; five received the conventional conditioning regimen consisting of cyclophosphamide and total body irradiation, while three received a reduced-intensity preparative regimen. Two patients died due to encephalopathy of unknown aetiology on days 10 and 35, and one patient died due to progression of ATLL 25 months after BMT. Five patients are currently alive and disease-free at a median of 20 months after BMT. Proviral human T-lymphotropic virus type-I (HTLV-I) DNA load in peripheral blood mononuclear cells (PBMCs) was assessed in four cases before and after BMT. HTLV-I proviral DNA load was reduced significantly after transplantation. Unrelated BMT is feasible for treatment of ATLL. Further studies in a larger number of cases are required to determine the optimal conditioning regimen and stem cell source.
Introduction
Adult T-cell leukaemia/lymphoma (ATLL) is a highly aggressive T-cell malignancy, which usually becomes resistant to conventional chemotherapy or even high-dose chemotherapy during its clinical course. 1 The median survival periods of patients with acute-and lymphomatype ATLL treated with chemotherapy are 7.4 and 13 months, respectively. 2, 3 About 40 cases of allogeneic bone marrow transplantation (BMT) from sibling donors have been reported to date. [4] [5] [6] [7] [8] [9] [10] [11] [12] The long-term survival of patients following BMT suggests that the graft-versus-leukaemia effect may eradicate human T-lymphotropic virus type-I (HTLV-I)-infected and ATLL cells. However, an HLA-identical sibling donor is not available for all patients suffering from ATLL, and only a few cases of allogeneic BMT from unrelated donors have been reported to date. 7, [13] [14] [15] Our hospital, Ehime Prefectural Central Hospital, is located in the Shikoku district of Japan, an area in which HTLV-1 infection is endemic. In 1999, we began performing unrelated BMT in patients with ATLL to improve the survival of patients with no available sibling donor.
Patients and methods
In all cases, the diagnosis of ATLL was based on clinical features, immunophenotype, presence of anti-HTLV-1 antibody and clonal integration of HTLV-1 proviral DNA. The subtypes of ATLL were defined as described previously. 16 In all cases, Southern Blotting analysis confirmed monoclonal integration of HTLV-1 provirus. The patient characteristics are shown in Table 1 . Eight patients with ATLL (acute-type, n ¼ 5; lymphoma-type, n ¼ 3) underwent BMT from unrelated donors, all of them were HTLV-1 antibody-negative. HLA typing was performed by the SBT method. Three patients were found to be matched at HLA-A, -B and -DRB1 loci by DNA typing. One patient was mismatched at one HLA locus, and four patients were mismatched at two HLA loci. Six patients, all of whom received the CHOP-V-MMV regimen prior to BMT, were in complete remission (CR), and these were the first responses to chemotherapy. Two patients were refractory to chemotherapy before transplantation. The median time from diagnosis to transplantation was 11 months (range, 6-28 months).
Five patients received a conventional conditioning regimen consisting of cyclophosphamide at a dose of 60 mg/kg once daily i.v. on days À6 and À5 (total dose, 120 mg/kg) and total body irradiation at a dose of 2 Gy twice daily on days À4, À3 and À2 (12 Gy/body). Three patients received a reduced-intensity conditioning regimen based on fludarabine. Two patients received busulfan at a dose of 4 ). GVHD prophylaxis consisted of treatment with cyclosporin and short-term methotrexate in five patients and with tacrolimus and short-term methotrexate in three patients.
All patients were cytomegalovirus (CMV)-seropositive before transplantation. CMV pp 65 antigenaemia assay was performed once a week after neutrophil engraftment.
The HTLV-I proviral DNA level was measured in the peripheral blood mononuclear cells (PBMCs) from four patients before and after BMT by real-time PCR (RT-PCR) with primers specific for HTLV-I pX.
Results
As shown in Table 1 , seven patients achieved engraftment, but one patient died before engraftment. All of the patients who achieved engraftment developed acute graft-versushost disease (GVHD). Four and three patients developed grade I and grade II acute GVHD, respectively. Three of six patients who survived for more than 100 days developed chronic GVHD.
To date, three patients have died, but five are currently alive and free of disease. Two patients died due to encephalopathy of unknown aetiology on days 10 and 35. Patient no. 7 was refractory to chemotherapy. In this patient, BMT was performed with a reduced-intensity conditioning regimen consisting of fludarabine and melphalan and total body irradiation. On day 7, the patient developed mild fever of 37.91C, and disorientation and hypoxia occurred on day 9. The patient's consciousness deteriorated, and she died on day 10. Patient no. 1 underwent BMT in CR, and the conditioning regimen consisted of cyclophosphamide and total body irradiation. On day 17, neutrophil engraftment was observed. After day 20, fever of approximately 40.01C was observed once a day, and systemic convulsion occurred on day 22. Cranial computed tomography at onset showed no remarkable findings. Viral encephalitis was suspected, so treatment with vidarabine was begun at a dose of 600 mg/day. However, the patient's consciousness was never restored and he died on day 35.
One patient died due to disease progression 25 months after transplantation. Figure 1 and Figure 2 show a Kaplan-Meier plot of overall survival and event-free survival, respectively. In the present study, the median Complications after BMT are shown in Table 2 according to the preparative regimen used. Five of seven patients examined developed CMV antigenaemia. These patients received prophylactic gancyclovir, but one patient who underwent conventional BMT developed CMV enterocolitis. One patient had haemorrhagic cystitis caused by adenovirus type 11. Two patients suffered from herpes zoster virus but were treated successfully with acyclovir.
We examined HTLV-I proviral DNA load in PBMCs in four patients before and after BMT (Table 3) . Proviral DNA load was reduced significantly in all four cases after transplantation (P ¼ 0.0499).
Discussion
Until recently, allogeneic haematopoietic stem cell transplantation for ATLL patients was not usually considered because of the patients' relatively high age and immunodeficient status. Recent improvements in conditioning regimens and supportive care for stem cell transplantation patients have facilitated allogeneic stem cell transplantation in elderly or immunocompromised patients. Usually, allogeneic stem cell transplantation is considered for those ATLL patients for whom an HLA-identical sibling donor is available. However, we have performed allogeneic BMT from unrelated donors to improve the survival of ATLL patients who have no sibling donors. Although the median observation time of 20 months is not yet sufficient to allow definitive conclusions to be drawn, the median disease-free survival period of 16.5 months and median overall survival of 20 months obtained using this procedure are promising. The relatively long survival periods of these patients seems to be due to the higher CR rate before BMT (75%). A previous retrospective study in Japan reported 124 cases of unrelated BMT for non-Hodgkin's lymphoma, which included 15 patients with ATLL. However, this was a multicentre study and the backgrounds of ATLL patients were not described in detail. None of the patients survived beyond 500 days after transplantation. 15 Three patients received a reduced-intensity preparative regimen. Two of these patients who received the reducedintensity preparative regimen in CR were of relatively high age (55 and 59 years old), but both have shown disease-free survival without complications for more than a year. In transplantation for treatment of ATLL, the conditioning regimen may be less effective for eradication of ATLL cells but the graft-versus-ATLL effect may eradicate ATLL cells. To avoid the toxicity of myeloablative conditioning regimens, a reduced-intensity conditioning regimen may be suitable not only for elderly patients but also for younger patients.
Two patients who underwent BMT in non-CR had short disease-free survival periods; one patient died on day 10, and the other relapsed 1 month after transplantation. To improve the results of treatment for non-CR ATLL patients, it is necessary to reconsider the conditioning regime to avoid transplantation-related mortality. In addition, cord blood transplantation may be considered to ensure that we do not miss the short CR period of ATLL patients.
Two patients died due to encephalopathy the origin of which could not be determined as we could not perform computed tomography and magnetic resonance imaging (MRI) because of the severity of the patients' illness. However, ATLL cells and Herpes Simplex Virus type-6 encephalitis may have been responsible for the encephalopathy in these patients. We could not examine the cerebrospinal fluid, so the relationship between HTLV-I and encephalopathy remains unclear. In solid organ transplantation, it has been reported that carriers of HTLV-1 do not develop myelopathy. 17 However, patients who received organ transplantation from donors carrying HTLV-1 develop myelopathy within a very short period. 18 In the present study, HTLV-I proviral DNA levels decreased after BMT, and thus it is unlikely that HTLV-I-associated encephalitis was the main cause of the encephalopathy in these patients. MRI and lumbar puncture should be performed before and after BMT.
HTLV-1 proviral DNA load can be used as a marker of the efficacy of ATLL treatment. In the present study, proviral DNA load was significantly decreased after transplantation in four cases. Reconstituted immunity against antigen presentation in ATLL patients after allogeneic stem cell transplantation has been reported to result in graft-versus-HTLV-I response, which may contribute to graft-versus-leukaemia effects. 19 Three of four patients whose HTLV-I proviral DNA load decreased significantly are currently alive in CR. The early disappearance of HTLV-I proviral DNA in PBMCs may be a prognostic factor in patients with ATLL treated by allogeneic BMT.
Similar to transplantation from a sibling donor, unrelated BMT can prolong survival of patients with ATLL. Thus, stem cell transplantation from an unrelated donor should still be considered even in ATLL patients with no sibling donor. The conditioning regimen should be refined CST ¼ conventional stem cell transplantation; RIST ¼ reduced intensity stem cell transplantation. CMV ¼ cytomegalovirus. Unrelated BMT for patients with ATLL K Nakase et al to maximise the antileukaemic effect and minimise toxicity, and future studies should be performed to determine the optimal source of stem cells.
